HUMA$1.06+0.00%

Fair $1.06+0.0%

HUMA

Humacyte, Inc.

Healthcare / BiotechnologyNasdaqGS

$1.06

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $1.06Fund rank 24/100 · Data gapFallback financials|

SA 2/F

F-Score: 3/9

High DebtLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-99.7M · quality 42.0/100

Data gap 24/100

Bear 5Yn/dn/d

Base 5Yn/dn/d

Bull 5Yn/dn/d

Return 0/100Downside 20/100Model quality 38/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

2/100

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 6Warnings: 2unknown: 6

No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific biotech pipeline model required: targets are disabled until product, probability, peak-sales and cash-runway data exists. Debt-to-Equity ratio is 11.40, above the 2.0 threshold ROE is -13.1%, below the 5% threshold

Thesis & Journal · HUMALocal privado en este navegador · Humacyte, Inc.

Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Tesis central

Bull caseBase caseBear case

CatalizadoresRiesgos

Kill criteria

Mi valoración / targetReview date

Sin guardar todavía.

Market Cap

$235M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-1313.4%

↓

Gross Margin

N/A

•

Debt/Equity

11.40

↑

No hay histórico de precio usable para pintar el gráfico TradingView.

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2020–2025 · 5 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

-5197.5%

FCF / Net income

2.59x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $2.0M · net income $-40.8M · FCF $-105.9M

2020-FY → 2025-FY

Gross margin

—— pts

Operating margin

-5306.0%— pts

Net margin

-2003.6%— pts

FCF margin

-5197.5%— pts

Metric	TTM	2025	2024	2023	2022	2021	2020
Income Statement
Revenue	$2.0M	$2.0M	$0.00	—	—	—	—
Net Income	$-40.8M	$-40.8M	$-148.7M	$-110.8M	$-12.0M	$-26.5M	$-66.5M
EPS	-0.26	-0.26	-1.26	-1.07	-0.12	-0.66	-11.54
Operating Margin	-5306.0%	-5306.0%	—	—	—	—	—
Net Margin	-2003.6%	-2003.6%	—	—	—	—	—
Balance Sheet
Debt/Equity	11.40	11.40	0.00	—	—	0.25	—
Cash Flow
Free Cash Flow	$-105.9M	$-105.9M	$-99.7M	$-75.6M	$-72.2M	$-81.4M	$-55.9M
Returns
ROE	-1313.4%	-1313.4%	282.3%	-817.8%	-10.2%	-21.7%	19.0%
Growth & Yield
EPS Growth	79.4%	79.4%	-17.8%	-791.7%	81.8%	94.3%	—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity